AlmirallShare, the open innovation platform of Almirall, S.A. (ALM) launches today a new call which aims to find partners to identify, validate or test new targets for the treatment of chronic immune-inflammatory diseases of the skin, such as psoriasis, atopic dermatitis and pemphigus vulgaris. All of them are severe diseases associated to significant comorbidities that have a profound impact in the quality of life of patients.
The call is open from July 23rd to October 31st, 2019, and is addressed to Scientists in Universities, research centres, start-ups, biotech’s or pharma companies worldwide.
Therapies start with an idea. Almirall would like to hear yours.
“Many chronic immune-inflammatory diseases, irrespective of the organ affected, share common mechanisms, pathways and players: psoriasis has therapies in common with multiple sclerosis and rheumatoid arthritis; atopic dermatitis with asthma; pemphigus with lupus, to name a few. We would be delighted to explore with our partners a target, pathway or therapy, related to any immune-inflammatory disease, that can be of use on a dermatological indication”, has pointed out Nuria Godessart, Head of Biology.
The researchers interested in participating in this new call have the opportunity to submit their proposals at sharedinnovation.almirall.com, where they can also find the complete basis of the call.
Significantly improving the conditions of the previous editions, Immune-inflammatory Diseases Under Your Skin offers grants up to 250,000 € and Scientific support to the selected proposals.
AlmirallShare was launched in 2017 as an open innovation R&D platform designed to facilitate the establishment synergistic collaborations in dermatological research and find innovative solutions in medical dermatology. By putting together Science and creativity of experts around the world and Almirall’s own expertise, this initiative aims to accelerate the generation of new treatments for skin diseases.
Thanks to the three previous calls, around 500 scientists are subscribed to the platform and more than 200 proposals have been received. Almirall has already started two research collaborations on preclinical models for atopic dermatitis with the University College of Dublin (Ireland) and the University of Sheffield (United Kingdom). On top of that, seven new partnerships with scientists from universities and research centres will start soon.
“We’re very excited with the response that this innovative platform has had among the scientific community all around the world and we’re also convinced about the success of this 4th Call for Proposals. AlmirallShare has become an important tool to implement Almirall’s R&D strategic partnerships”, has underlined Maribel Crespo, AlmirallShare leader.
AlmirallShare is an open innovation platform designed to facilitate the establishment of collaborations in dermatological research and find innovative solutions in medical dermatology. By putting together Science and creativity of experts around the world and Almirall’s own expertise, the AlmirallShare initiative will accelerate the generation of new treatments for skin conditions.
Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel their best. We support healthcare professionals in continuous improvement, bringing our innovative solutions where they are needed.
The company, founded almost 75 years ago and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its shareholders and its decision to help others by understanding their challenges and using Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. Almirall has more than 1,800 employees.